Skip to main content
TipRanks
Go Ultimate75% OFF

Demant (WILYY) AI Stock Analysis

7 Followers
WILYY

Demant

(Other OTC:WILYY)

Select Model
Rating:70Outperform
Price Target:$28.00â–²(8.98% Upside)
Action:upgraded
Date:08/19/26

The overall score reflects a fundamentally profitable business with strong margins, robust recent growth and upgraded guidance, supported by clear bullish price momentum, while a leveraged balance sheet, volatile cash and earnings trends, and a rich valuation without dividend support keep the rating in the upper-middle of the range rather than at the top.

Positive Factors
Organic Growth and Product MomentumStrong organic growth alongside successful Oticon Zeal adoption indicates durable demand for Demant’s hearing solutions. Continued product momentum can support market share, premium pricing and revenue expansion over the next several quarters, particularly in hearing aids.
Negative Factors
Higher LeverageThe more debt-heavy capital structure reduces financial flexibility and increases sensitivity to earnings pressure. Leverage remaining above management’s target range could constrain future investment capacity and make refinancing or integration execution more demanding.

Demant (WILYY) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%WILYY+56.77%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$11.23B
Dividend Yield
―
Average Volume (3M)
2,243
Price to Earnings (P/E)
45.4
Beta (1Y)
0.85
Revenue Growth
17.46%
EPS Growth
-23.56%
Country
US
Employees
26,704
Sector
General
Sector Strength
55
Industry
Medical - Devices

Demant Business Overview & Revenue Model

Company Description

Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. It engages in the development, manufacture, and wholesale of hearing aids; owning and operating hearing care clinics; and offers...

Demant Earnings Call Summary

Earnings Call Date:Aug 11, 2026(Q2-2026)|% Change Since:20.06%|Next Earnings Date:Feb 09, 2027
Earnings Call SentimentPositive

The call presented multiple strong operational and financial positives: robust reported revenue growth (15%), gross profit expansion (+17%) and gross margin improvement (+1.1 ppt), solid cash generation, successful commercial momentum driven by Oticon Zeal and the new Oticon Reveal product positioning, and upgraded full-year guidance. Offsetting these positives are elevated and increased special items tied to acquisitions and restructurings, FX headwinds, regional softness (notably China and managed care in the U.S.), and the risk of competitive launches in H2. On balance, the company’s financial performance, product momentum, successful integration progress and strengthened outlook outweigh the headwinds and one-off costs.

Positive Updates

Strong Reported Revenue Growth
Group reported revenue growth of 15% in H1 2026, composed of 7% organic growth, 10% acquisitive growth (predominantly from KIND), and a -3% FX effect.

Negative Updates

Increased Special Items and Integration Costs
Special items for full-year 2026 were increased to DKK 400 million (from DKK 325 million). KIND integration costs are now estimated at DKK 150 million (up from DKK 125 million) and cost-savings implementation severance/implementation costs at DKK 250 million (up from DKK 200 million). H1 special items totaled DKK 216 million (predominantly KIND).

Company Guidance

Management upgraded 2026 guidance: organic revenue growth is now expected at 6–7% (up from 3–6%) and EBIT before special items at DKK 4.4–4.8bn. They also set total special items at DKK 400m (up from DKK 325m), with KIND integration costs of DKK 150m (was DKK 125m) and cost‑saving implementation costs of DKK 250m (was DKK 200m); the cost‑effectiveness program is now expected to deliver DKK 300m (vs DKK 250m) and KIND is forecast to contribute DKK 325m to EBIT (vs DKK 300m), while a tariff refund of DKK 25m is expected in H2. For context H1 performance underpinning the upgrade included reported group revenue +15% (organic +7%, acquisitive +10%, FX -3%), gross profit ~DKK 10bn (+17%, gross margin +1.1pp), EBIT before special items DKK 2.134bn (16.5% margin), cash flow from operations DKK 1.6bn (+6%), and net leverage down to ~3.0 with an expectation to be slightly above the 2.0–2.5 target range by year‑end.

Demant Financial Statement Overview

Summary

Strong and consistently high gross margins and solid operating profitability are offset by a stretched balance sheet, rising leverage above twice equity, and volatile net income and free cash flow trends.

Income Statement

75Positive

Balance Sheet

58Neutral

Cash Flow

70Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue24.98B22.97B22.42B22.44B19.70B17.91B
Gross Profit19.08B17.37B17.09B16.54B14.67B13.46B
EBITDA5.99B5.43B5.80B5.75B4.29B4.48B
Net Income1.64B1.54B2.39B1.79B2.08B2.51B
Balance Sheet
Total Assets40.03B39.07B32.45B30.55B29.86B24.86B
Cash, Cash Equivalents and Short-Term Investments1.50B1.33B1.11B1.14B1.13B1.17B
Total Debt20.28B20.99B15.68B14.45B15.08B11.34B
Total Liabilities28.71B29.16B22.81B21.21B21.30B16.88B
Stockholders Equity11.24B9.84B9.56B9.26B8.56B7.98B
Cash Flow
Free Cash Flow3.47B3.18B3.30B3.58B1.70B2.55B
Operating Cash Flow4.08B3.80B4.08B4.23B2.62B3.27B
Investing Cash Flow-6.09B-6.79B-1.83B-1.77B-3.33B-1.30B
Financing Cash Flow2.50B3.23B-2.24B-2.41B934.00M-1.78B

Demant Technical Analysis

Technical Analysis SentimentPositive
Last Price25.69

Price Trends

50DMA25.36Positive
100DMA23.54Positive
200DMA20.03Positive

Market Momentum

MACD0.23Positive
RSI42.77Neutral
STOCH13.31Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WILYY, the sentiment is Positive. The current price of 25.69 is below the 20-day moving average (MA) of 27.16, above the 50-day MA of 25.36, and above the 200-day MA of 20.03, indicating a neutral trend. The MACD of 0.23 indicates Positive momentum. The RSI at 42.77 is Neutral, neither overbought nor oversold. The STOCH value of 13.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for WILYY.

Demant Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

WILYY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GEHCGEHC79Outperform$37.54B17.5119.85%0.17%6.87%-2.26%
DXCMDXCM73Outperform$31.08B32.1736.50%―13.03%40.88%
WILYYWILYY70Outperform$10.59B45.4215.31%―17.46%-23.56%
ZBHZBH69Neutral$19.53B26.006.05%0.93%6.98%-2.22%
PHGPHG67Neutral$29.39B27.228.44%3.26%――
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
COCHCOCH53Neutral$52.13M-1.80-9999.00%―11.06%64.70%

* General Sector Average

Performance Comparison

-50%-25%0%25%50%WILYYDXCMPHGZBHCOCHGEHCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
WILYY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
WILYYDemant A/S Unsponsored ADR25.699.4458.09%
DXCMDexcom81.6121.4435.63%
PHGKoninklijke Philips N.V.30.143.5313.25%
ZBHZimmer Biomet Holdings101.4113.2715.06%
COCHEnvoy Medical, Inc. Class A6.92-0.74-9.67%
GEHCGe Healthcare Technologies Inc.82.9612.0817.05%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 19, 2026